Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer

Jennifer E. Klomp(Michigan State University), Clint A. Stalnecker(University of North Carolina at Chapel Hill)

Science

June 6, 2024

10.1126/science.adk0850

Cited by 79

Related Papers

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

|Nature|2024|319

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

|Nature|2024|175

Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic Cancer

|Cancer Research|2022|160

Time-Variant SRC Kinase Activation Determines Endothelial Permeability Response

|Cell chemical biology|2019|38

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.

|UNC Libraries|2024|12